<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844933</url>
  </required_header>
  <id_info>
    <org_study_id>INS011-16-085</org_study_id>
    <nct_id>NCT02844933</nct_id>
  </id_info>
  <brief_title>Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INSYS Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INSYS Therapeutics Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of Cannabidiol Oral Solution on
      hyperphagia-related behavior in subjects with Prader-Willi Syndrome (PWS). The secondary
      objectives of this study are to assess the efficacy, safety and tolerability, impact on
      quality of life, and impact on physical activity of Cannabidiol Oral Solution in subjects
      with PWS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the total score of the Hyperphagia Questionnaire for Clinical Trial (HQ-CT)</measure>
    <time_frame>Baseline through Study Completion/ Early Withdrawal (within 13 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Body-Weight</measure>
    <time_frame>Baseline through Study Completion/ Early Withdrawal (within 13 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Rate from Baseline through Study Completion</measure>
    <time_frame>Baseline through Study Completion (within 13 weeks)</time_frame>
    <description>Responder is defined as 6-point decrease on the HQ-CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Global Impression of Change and Severity (PGI-C)</measure>
    <time_frame>Baseline through Study Completion/Early Withdrawal (within 13 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Three Factor Eating Questionnaire - 18-item Version (TFEQ-R18)</measure>
    <time_frame>Baseline through Study Completion/Early Withdrawal (within 13 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Quality of Life (PROMIS Life Satisfaction and Positive Affect Questionnaires)</measure>
    <time_frame>Baseline through Study Completion/Early Withdrawal (within 13 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Physical Activity (PROMIS Physical Activity and Fatigue questionnaires)</measure>
    <time_frame>Baseline through Study Completion/Early Withdrawal (within 13 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol oral solution (40 mg/kg/day) divided into two daily doses with a standard meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo solution divided into two daily doses with a standard meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  In the opinion of the investigator, the parent(s)/caregiver(s) is (are) willing and
             able to comply with the study procedures and visit schedules, including venipuncture,
             and the visit schedules

          -  Voluntarily consents to participate and provides written informed consent prior to any
             protocol-specific procedures

        Exclusion Criteria:

          -  History or current use of over-the-counter medications, dietary supplements, or drugs
             (including nicotine and alcohol) outside protocol-specified parameters

          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of
             the investigator, might compromise:

               1. the safety or well-being of the participant or study staff;

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding);

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elkashef, MD</last_name>
    <role>Study Director</role>
    <affiliation>INSYS Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>(602) 910-2617</phone>
    <email>InsysCBD@insysrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>560-626-5472</phone>
      <email>mgordon@email.arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's, UC San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>858-966-8453</phone>
      <email>rwinograd@rchsd.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>319-335-7432</phone>
      <email>rachel-bisbee@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Kansas , Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>913-588-1800</phone>
      <email>cweber3@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>410-614-8583</phone>
      <email>kfehily2@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>918-619-4304</phone>
      <email>Sharnella-Goudeau@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Research and Innovation | MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Coordinator</last_name>
      <phone>253-403-2699</phone>
      <email>ccanorro@multicare.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 22, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidiolex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

